Nobias Therapeutics is a clinical-stage company developing novel small-molecule therapeutics for rare diseases, focusing initially on pediatric indications and expanding to adults and non-rare indications. This description is self-described.

Nobias Therapeutics

AbbVie engages in pharmaceutical research and development to provide innovative solutions for patients.

AbbVie

西安杨森制药有限公司专注于医药创新解决方案，关注人们的健康，致力于研发、引进和生产药品与健康解决方案。

西安杨森制药有限公司

Amgen Bangladesh is a subsidiary of Amgen Inc., one of the world's leading biotechnology companies. The company is dedicated to discovering, developing, manufacturing, and delivering innovative human therapeutics. It focuses on areas of high unmet medical need, leveraging expertise in biology, chemical engineering, and a variety of other scientific disciplines to develop medicines that can help millions of patients around the world.

George Rathmann

Amgen Bangladesh

Nobias Therapeutics is a clinical-stage company developing novel small-molecule therapeutics for rare diseases. The firm has unique access to genomic and health datasets and collaborates with pediatric academic medical centers across North America to advance drug discovery for genetically-defined rare diseases.

Nobias Therapeutics | 706 followers on LinkedIn. Clinical-stage company developing novel small molecule therapeutics for rare diseases | Nobias Therapeutics is a clinical-stage company developing novel small molecule therapeutics for rare diseases. Our unique access to rich genomic and health datasets and strong relationships with pediatric academic medical centers across North America allow us to rapidly advance drug discovery for genetically-defined rare diseases, with an initial focus on pediatric indications, but expansion opportunities in adults and non-rare indications.

Biotech Professional - Strategy, Planning, Operations and Business Development

Patrick Dougherty

Bruce Goldsmith

at The Children's Hospital of Philadelphia

Hakon Hakonarson

Platform Engineer at Nobias Therapeutics

Abhishek Shakya

Thanks to the MEC team for a great event. Nobias is incredibly lucky to be part of the MEC portfolio and to have the support of such a great team!

Thanks again to the team at the LDV Vision Summit ( https://lnkd.in/dQyE7b9 ) for the opportunity for our CEO, Neil Inala , to speak with Olga Troyanskaya , Elizabeth Neumann , and moderator Laura Smoliar about advancements in visual tech and machine learning in the life sciences. For those who were not able to tune into the summit live, the transcript and video are now posted here: https://lnkd.in/d7UPuTZd

We've recently been accepted into the NVIDIA Inception program for startups. We're very excited by all the opportunities, resources, and capabilities this amazing program unlocks for us. Thanks very much to the team at NVIDIA for all their help! https://lnkd.in/ev2sJWeu

Nobias CEO Neil Inala will join a stellar Life Sciences Panel at the 2024 LDV Capital #LDVVisionSummit tomorrow! #AI advances are revolutionizing our world and #medicine and #drugdevelopment will be no different. Check out the agenda and register here: https://lnkd.in/dQyE7b9

If you are interested in connecting with Nobias at the BIO CEO and Investor Conference to discuss the results of our recent phase II clinical trial in 22q11 deletion syndrome (NB-001), our lymphatic anomalies program (NB-002), or to discuss other drug development opportunities using our cutting-edge generative-AI based target and molecule discovery platform, please reach out to us via LinkedIn or via the conference reservation system.

Our CEO Neil Inala recently attended the AI-Driven Drug Discovery Summit in Boston. It was a great couple of days with many interesting presentations from groups at the forefront of the use of AI techniques in drug discovery. The talks were well-attended and the questions asked were quite insightful.

November is 22q Awareness Month in the US ( https://lnkd.in/gKNHcDqm ); and November 22nd is 22q Awareness Day in Europe. We join the 22q11.2 Syndromes community ( http://www.22q.org/ ) to build awareness about 22q11.2 deletion and duplication as we recognize the incredible perseverance of this community in striving to overcome the many obstacles they face. Nobias is committed to advancing our clinical program for the treatment of certain neuropsychiatric conditions associated with #22q . We thank the many patients and families that have been part of our development journey to date. #22qfamily

Metric
Company Name	Nobias Therapeutics	AbbVie	西安杨森制药有限公司	Amgen Bangladesh
Symbol
MSH ID	COM:NOBIASTX	AR:COM:ABBVIE	CN:COM:XIAN-JANSSEN	COM:AMGENBD
Market	PRIVATE	PRIVATE	PRIVATE	PRIVATE
Sector	Healthcare & Health Services	Healthcare & Health Services	Healthcare & Health Services	Healthcare & Health Services
Industry	Biotechnology	Pharmaceuticals	Pharmaceuticals	Biotechnology
Country	US	AR	CN
Stage	Series A
Employee Count				10.00K
Website	nobiastx.com	abbvie.com.ar	xian-janssen.com.cn	amgenbd.com
LinkedIn	nobias-therapeutics
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic	270
Web Traffic Growth	-0.35
Valuation
Raised Capital	3.75M

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

NOBI

COM:NOBIASTX

Nobias Therapeutics

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue